A Phase 1 study Evaluating the Safety, Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors .
Latest Information Update: 18 Mar 2025
At a glance
- Drugs TL 938 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 18 Mar 2025 New trial record